Contract research firm Inotiv's Q1 operating loss widens

Inotiv

09/02/2026 12:08

Overview

Contract research firm's fiscal Q1 2026 revenue rose 0.8% yr/yr

Adjusted EBITDA for fiscal Q1 2026 missed analyst expectations

Company exited two leased facilities as part of site optimization plan

Outlook

Company did not provide specific guidance for future quarters or full year

Result Drivers

DSA REVENUE GROWTH - DSA segment revenue increased by 12% due to higher demand for discovery pharmacology and safety assessment services

RMS REVENUE DECLINE - RMS segment revenue decreased by 5.4%, primarily due to lower non-human primate volumes sold

OPERATING LOSS INCREASE - Operating loss increased due to higher costs in RMS segment despite some cost reductions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Miss*
$120.90 mln
$120.91 mln (2 Analysts)
Q1 Net Income
-$28.40 mln
Q1 Adjusted EBITDA
Miss
$1.80 mln
$7.61 mln (2 Analysts)
Q1 Capex
$5.20 mln
Q1 Operating Income
-$16.30 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inotiv Inc is $2.75, about 557.4% above its February 6 closing price of $0.42

Press Release: ID:nGNX6nHM0x

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)